ABOUT US
LEADERSHIP
PRIVACY

Our Story

Leadership Team

  1. Home
  2. >
  3. Leadership
We have assembled an
accomplished and energetic
team with expertise in
commercial, research, and
medical affairs

Management Team

Jackson Zhu

Chief Executive Officer, Founder
Bio

I Jackson Zhu, MD, MBA, is the Chief Executive Officer and Founder of MBM, where he leads an integrated team of business, medical and scientific experts in building the company’s commercialization platform capabilities. He has worked in the pharmaceutical industry for more than 20 years, and has rich experience in a wide spectrum of roles including corporate strategy, M&A, business development and operations. Previously, he was the Greater China General Manager of Catalent, the world’s largest R&D and advanced drug delivery technology solution provider. He was also a VP and Europe Regional Business Head of Boehringer Ingelheim, focused on operations and business strategy. He was elected as a Global Director of Precision Medicine as part of the World Economic Forum.
x

 

Ariel Wu

VP of Operations, Co-Founder

Bio

Ariel Wu is the Vice President of Business Operations and Co-Founder of MBM. She is responsible for managing MBM’s operational activities, including finance, administration, personnel, and legal affairs. She has more than 20 years pharmaceutical industry experience with tenures in companies such as Johnson & Johnson, Roche and GlaxoSmithKline, taking on varied roles including product management, sales & marketing and business development. She managed and launched several blockbuster products in oncology and antiviral fields and was awarded GSK Asia Pacific President Award for outstanding performance.
x

Pang Liping

VP of Sales & Marketing, Partner

Bio

Pang Liping is the Vice President of Sales and Marketing Operations and is responsible for leading a rapidly growing sales and marketing unit within MBM. He has more than 20 years experience in pharmaceutical and diagnostics sales & marketing, working for companies such as CSPC Pharmaceutical Group, BGI Genomics and Ebien Biotech. His successes include launching and growing a new cancer screening service that became the top-selling product in China, and managing a pharmaceutical sales department with over ¥2B in annual sales.
x

Jackson Zhu

Chief Executive Officer, Founder
Bio

Jackson Zhu, MD, MBA, is the Chief Executive Officer and Founder of MBM, where he leads an integrated team of business, medical and scientific experts in building the company’s commercialization platform capabilities. He has worked in the pharmaceutical industry for more than 20 years, and has rich experience in a wide spectrum of roles including corporate strategy, M&A, business development and operations. Previously, he was the Greater China General Manager of Catalent, the world’s largest R&D and advanced drug delivery technology solution provider. He was also a VP and Europe Regional Business Manager of Boehringer Ingelheim, focused on operations and business strategy. He was elected as a World Economic Forum global council member.
x

 

Ariel Wu

VP of Operations, Co-Founder

Bio

Ariel Wu is the Vice President of Business Operations and Co-Founder of MBM. She is responsible for managing MBM’s operational activities, including finance, administration, personnel, and legal affairs. She has more than 20 years pharmaceutical industry experience with tenures in companies such as Johnson & Johnson, Roche and GlaxoSmithKline, taking on varied roles including product management, sales & marketing and business development. She managed and launched several blockbuster products in oncology and antiviral fields and was awarded GSK Asia Pacific President Award for outstanding performance.
x

Shawn Liu

Vice President of Sales & Marketing, Partner

Bio

Shawn Liu is Vice President of professional marketing of MBM. He has 16 years experience of marketing & sales management, strategic planning, establishing new business model, and key brands management in top level MNCs, including Bayer, Astra-Zeneca, and Roche.
x

Lyon Chen

Chief Scientific Officer

Bio

Lyon Chen, PhD, is the Chief Scientific Officer and one of the co-inventors of MBM’s red blood cell liquid biopsy platform and is leading the research team in developing the technology for early cancer screening. He is also a principal investigator at Nanjing University where his research focus is on computational biology, genomics, and epigenetics. Previously, he was a senior strategy manager in GenScript Biotech Corporation, helping to establish the company’s gene editing and bispecific antibody platform. He graduated with a PhD in molecular biology from University of Southern California.
x

Margot Tong

Clinical R&D Director

Bio

Margot Tong, PhD, is the Clinical R&D Director, and is responsible for leading MBM’s clinical research lab operations and projects in digital pathology. Before joining MBM, she was a senior director of genetic technology and medical science at Shanghai Mediwell Biotechnology; focusing on in vitro diagnostic product development and quality control system management. She was previously with Shanghai Daan Medical Laboratory, helping to build its first non-invasive prenatal screening technology platform. She graduated from the Baylor College of Medicine and did her post-doc at Cornell Medical College Hospital.
x

Vivian Mao

Medical Affairs Director

Bio

Vivian Mao, MSc, is the Medical Department Director, and is leading MBM’s multi-center clinical research collaborations and medical KOL engagement. Previously, she was a medical marketing manager at Jilin Yatai Pharmaceutical and Shanghai Sai’an Biomedical Technology, where she gained extensive experience in national multi-center clinical studies, product marketing strategy in both tumor drug development and in vitro diagnostic. She has a master’s degree in genetics from Northeast Normal University. x

Shelly Sun

Regulatory Affairs and Quality Management Director

Bio

Shelly Sun is the Regulatory Affairs and Quality Management Director, and is responsible for MBM’s product registration and production QC system. Previously, she worked in a similar capacity at Beijing Health Guard Biotechnology and Walvax Biotechnology and was responsible for the clinical trials and product registration and industrial manufacturing QC of two HPV vaccine products. She was a bioengineering graduate of Jiangsu Ocean University.
x

Robin Chan

Business Development Director

Bio

Robin Chan is the Business Development Director, and is developing MBM’s B2B commercial research partnerships and overseas expansion corporate strategy. Before switching over to the business side of biotech, he was previously an Assistant Professor at Columbia University Medical Center where he established its first lipidomics research facility. He research focus on lipid metabolism in neurodegeneration, infectious disease and cardiovascular disease has resulted in over 30 publications. He has a PhD in Biochemistry from National University of Singapore, and a MBA from Columbia Business School.
x

The revolution requires
the right people.

Advisors

David J Kerr

Oxford University

Bio

Professor David Kerr is a professor of cancer medicine at the University of Oxford in Oxford, England. He is recognized internationally for his work in the research and treatment of colorectal cancer, and has published more than 400 papers. His clinical research into adjuvant therapy of early stage colorectal cancer has contributed to saving thousands of lives over the past four decades. He has founded three university spin-out companies: COBRA Therapeutics, Celleron Therapeutics, and Oxford Cancer Biomarkers. In 2002, he was appointed Commander of the British Empire by Queen Elizabeth and in 2010 was elected president of the European Society for Medical Oncology.x

 

John Maddison

Room4

Bio

Dr. John Maddison is a director in Room4 and has over 20 years of diverse commercial experience in the development, architecture design and management of artificial intelligence and machine learning projects. He is currently involved in leading multiple machine and deep learning A.I. projects with applications for automatic cell classification, IHC scoring, cell and tissue identification. He has filed 20+ international patents in the area of image processing using A.I. He is a member of the Institution of Engineering and Technology, a Chartered Engineer and a member of the Chartered Management Institute. He obtained his Ph.D. in electronic and information engineering from the University of Huddersfield and MBA from the University of Liverpool.
x

William E Johnson

Boler Biotech Consulting

Bio

Mr. William Johnson is a managing partner at Boler Biotech Consulting. He is a partner and advisor to several company leaders and boards, and venture or industry-backed investment groups. He provides business expertise in sourcing, investigating and assessing scientific and market potential of new technologies, therapies and companies, developing and negotiating contracts for industry-academic partnerships, as well as helping his clients start up and guide transactional and project finances of early-stage portfolio ventures. He has a broad-based scientific background and earlier worked for organizations including Novartis, Wyeth, EMD Millipore, Broad Institute and Mayo Clinic.
x

Håvard E Danielson

University of Oslo/Institute of Cancer Genomics and Informatics

Bio

Professor Håvard E. Danielsen is a geneticist with a PhD in medicine from the University of Oslo. He is the Director of the Institute for Cancer Genetics and Informatics at Oslo University Hospital (Norway) and holds positions at the Department of Informatics, University of Oslo, and at Nuffield Division of Clinical Laboratory Sciences at the University of Oxford. Danielsen is PI of the DoMore! project, which was the winner of a prestigious Lighthouse Project grant from the Norwegian Research Council. His research focuses primarily on DNA- and chromatin organization, using informatics as a tool to study genomic changes in cancer. x

 

en_USEnglish